Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents Within the IMerge Phase 2 Study

Dr Uwe Platzbecker reviews data on imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.